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Myocarditis   
Plan of the Lecture   
• Definition 
• Epidemiology 
• Risk factors 
• Etiology 
• Mechanisms  
• Classification 
• Clinical investigation 
• Diagnosis 
• Treatment   
• Prognosis 
• Prophylaxis 
• Abbreviations  
• Diagnostic and treatment 
guidelines 
http://circ.ahajournals.org/content/circulationaha/113/6/876/F1.large.jpg 
Definition  
Myocarditis is an inflammatory disease of the myocardium 
with a wide range of clinical presentations, from subtle to 
devastating, diagnosed by established histological, 
immunological and immunohistochemical criteria. 
http://eurheartj.oxfordjournals.org/content/34/33/2636 http://emedicine.medscape.com/article/156330-overview 
Epidemiology   
  
http://emedicine.medscape.com/article/156330-overview#a6 
• Incidence is usually estimated at 1-10 cases per 100,000 
persons.  
• Incidence of positive right ventricular biopsy findings in 
patients with suspected myocarditis is highly variable (ranging 
from 0-80%).  
• According to estimates, as many as 1-5% of patients with 
acute viral infections may have involvement of the 
myocardium. 
• No particular race predilection is noted for myocarditis except 
for peripartum cardiomyopathy that appears to have a higher 
incidence in patients of African descent. 
• The incidence of myocarditis is similar between males and 
females. 
• Patients are usually fairly young.   
Risk Factors and Etiology: 1   
  Worldwide, the most common cause is Chagas' disease, an illness 
endemic to Central and South America that is due to infection by the 
protozoanTrypanosoma cruzi. 
Infections 
• Viral (adenovirus, parvovirus B19, coxsackie virus, human 
immunodeficiency virus (HIV), enterovirus, rubella virus, poliovirus, 
cytomegalovirus, human herpesvirus, and possibly hepatitis C), 
• Protozoan (Trypanosoma cruzi causing Chagas disease and 
Toxoplasma gondii), 
• Bacterial (Brucella, Corynebacterium diphtheriae, 
gonococcus, Haemophilus influenzae, Actinomyces,Tropheryma 
whipplei, Vibrio cholerae, Borrelia burgdorferi, leptospirosis, 
and Rickettsia, Mycoplasma pneumoniae). 
https://en.wikipedia.org/wiki/Myocarditis#Causes 
Risk Factors and Etiology: 2   
  •  Fungal (Aspergillus). 
• Parasitic (ascaris, Echinococcus granulosus, Paragonimus 
westermani, schistosoma, Taenia solium,Trichinella spiralis, visceral 
larva migrans, and Wuchereria bancrofti). 
• Bacterial myocarditis is rare in patients without immunodeficiency. 
• Toxins (drugs, including alcohol, anthracyclines,  chemotherapy, 
antipsychotics, also some designer drugs such as mephedrone. 
• Immunologic (allergic (acetazolamide, amitriptyline), rejection after 
a heart transplant, autoantigens (scleroderma, systemic lupus 
erythematosus, sarcoidosis, Kawasaki disease, etc. ), toxins 
(arsenic, toxic shock syndrome toxin, carbon monoxide, or snake 
venom), heavy metals (copper or iron). 
• Physical agents (electric shock, hyperpyrexia, and radiation). 
https://en.wikipedia.org/wiki/Myocarditis#Causes 
Mechanisms     
(Viral and Autoimmune) 
http://eurheartj.oxfordjournals.org/content/34/33/2636 
• There is evidence for viral and autoimmune mechanisms, acting 
in individuals with or without a genetic predisposition. 
• Enteroviruses that preferentially enter cardiomyocytes via 
specific receptors cause severe cytopathic effects due to virus 
replication in the first 2 weeks post-infection.  
• As a consequence, a humoral and cellular immune response, 
mainly consisting of macrophages and CD4+ and CD8+ T- 
lymphocytes, leads to the elimination of the infectious agent 
within 2 weeks following infection.  
• The ongoing infection and inflammation trigger autoimmune 
reactions in the heart, most likely as a result of myocyte necrosis 
and subsequent release of self-antigens previously hidden to the 
immune system.  
Mechanisms     
(From Myocarditis to Dilated Cardiomyopathy) 
http://eurheartj.oxfordjournals.org/content/34/33/2636 
Mechanisms 
(Histopathology and Immunopathology) 
  
http://eurheartj.oxfordjournals.org/content/34/33/2636 
Acute lymphocytic 
myocarditis (first row), chronic 
lymphocytic myocarditis 
(second row), sarcoidosis 
(third row), and giant cell 
myocarditis (fourth row). Left 
column = haematoxylin-eosin; 
middle column = staining with 
anti-CD3 antibody (pan T 
lymphocyte marker); right 
column = staining with anti-
CD68 antibody (macrophage 
marker).  
Mechanisms 
(Histopathology and Immunopathology) 
  
http://eurheartj.oxfordjournals.org/content/34/33/2636 
Short-axis (upper line) and long-axis (lower line) images of a patient with acute 
myocarditis. In the first two columns, cine-SSFP images are shown in diastole 
and systole and suggest absence of any wall motion abnormality. In the next 
column, T2-weighted edema images demonstrate the presence of patchy focal 
edema in the subepicardium of the inferolateral wall (red arrows). In the last 
column, T1-weighted late gadolinium enhancement (LGE) images demonstrate 
presence of subepicardially distributed LGE (red arrows) which is typical for 
acute myocarditis. 
Classification 
(International Classification of Diseases (ICD) 
apps.who.int/classifications/icd10/browse/2016/en#/I46 
 I01.2 Acute rheumatic myocarditis 
I40.0 Infective myocarditis 
I40. 1Isolated myocarditis 
I40.8 Other acute myocarditis 
I40.9 Acute myocarditis, unspecified 
I41* Myocarditis in diseases classified 
elsewhere 
I41.0* Myocarditis in bacterial diseases 
classified elsewhere (diphtheritic 
(A36.8†), gonococcal (A54.8†), 
meningococcal (A39.5†), syphilitic 
(A52.0†), tuberculous (A18.8†) 
 
 
I41.1* Myocarditis in viral 
diseases classified elsewhere 
(influenzal myocarditis (acute) 
(J10.8†, J11.8†, J09†, B26.8†) 
I41.2* Myocarditis in other 
infectious and parasitic 
diseases classified elsewhere 
(Chagas disease (chronic) 
(B57.2†, B57.0†, B58.8†) 
I41.8* Myocarditis in other 
diseases classified elsewhere 
(rheumatoid myocarditis 
(M05.3†), sarcoid myocarditis 
(D86.8†) 
I51.4 Myocarditis, unspecified 
(myocardial fibrosis) 
 
Classification 
(Etiology, Cell Type, Clinical Type) 
https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
Classification 
(Lieberman’ Classification) 
http://emedicine.medscape.com/article/156330-overview#a4 
• Fulminant myocarditis: follows a viral prodrome; distinct onset of 
illness consisting of severe cardiovascular compromise with 
ventricular dysfunction and multiple foci of active myocarditis; 
either resolves spontaneously or results in death. 
• Acute myocarditis: less distinct onset of illness, with established 
ventricular dysfunction; may progress to dilated cardiomyopathy. 
• Chronic active myocarditis : less distinct onset of illness, with 
clinical and histologic relapses; development of ventricular 
dysfunction associated with chronic inflammatory changes 
(including giant cells). 
• Chronic persistent myocarditis: less distinct onset of illness; 
persistent histologic infiltrate with foci of myocyte necrosis but 
without ventricular dysfunction (despite symptoms, e.g., chest 
pain, palpitations). 
Classification 
(The Dallas Classification (1987)) 
http://emedicine.medscape.com/article/156330-workup#c12 
Initial biopsy: 
• Myocarditis: myocardial necrosis, degeneration, or both, in 
the absence of significant coronary artery disease with 
adjacent inflammatory infiltrate with or without fibrosis, 
• Borderline myocarditis: inflammatory infiltrate too sparse or 
myocyte damage not apparent, 
• no myocarditis, 
Subsequent biopsy: 
• Ongoing (persistent) myocarditis with or without fibrosis, 
• Resolving (healing) myocarditis with or without fibrosis, 
• Resolved (healed) myocarditis with or without fibrosis. 
Classification 
(WHO Marburg Сriteria (1996)) 
http://carditis.net/whfmyoca.htm 
First biopsy: 
1. Acute (active) myocarditis: a clear-cut infiltrate (diffuse, focal or 
confluent) of >14 leukocytes/mm² (preferably activated T-cells).   
2. Chronic myocarditis : an infiltrate of >14 leukocytes/mm² 
(diffuse, focal or confluent, preferably activated T-cells).   
3. No myocarditis: No infiltrating cells or <14 leukocytes/mm². 
Subsequent biopsies: 
1. Ongoing (persistent) myocarditis. Criteria as in 1 or 2 (features of 
an acute or chronic myocarditis). 
2. Resolving (healing) myocarditis. Criteria as in 1 or 2 but the 
immunological process is sparser than in the first biopsy. 
3. Resolved (healed) myocarditis. Corresponds to the Dallas 
classification. 
Clinical Investigation  
(Signs and Symptoms) 
• The clinical signs of myocarditis include fever, cardiac rhythm 
disturbance (tachycardia, bradycardia, and arrhythmia), 
hypotension, gallop rhythm, rales, jugular venous dilatation, 
and cardiac tamponade. 
• Flu-like symptoms: chills, fever, headache, muscle aches, 
general malaise. 
• Cardiac symptoms (a few hours to a few days after the initial 
signs and symptoms): heart failure, chest pain due to 
pericardial irritation, symptoms associated with heart block 
and arrhythmia.  
• Gastrointestinal symptoms: decreased appetite, nausea, 
vomiting, and diarrhea. 
 
https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
Clinical Investigation  
(Course of the Disease) 
• The primary signs and symptoms and disease progression of 
myocarditis are relatively easy to grasp.  
• The inflammatory phase lasts one to two weeks, and is 
followed by a recovery phase.  
• Myocarditis causes myocardial necrosis and inflammation, 
which result in cardiac dysfunction and failure.  
• Myocarditis usually manifests in an otherwise healthy person 
and can result in rapidly progressive (and often fatal) heart 
failure and arrhythmia  
http://emedicine.medscape.com/article/156330-overview  https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
Clinical Investigation  
(Specific Findings in Special Cases) 
• Sarcoid myocarditis: lymphadenopathy, also with arrhythmias, 
sarcoid involvement in other organs (up to 70%), 
• Acute rheumatic fever: usually affects heart in 50-90%; 
associated signs, such as erythema marginatum, 
polyarthralgia, chorea, subcutaneous nodules (Jones criteria), 
• Hypersensitive/eosinophilic myocarditis: pruritic 
maculopapular rash and history of using offending drug, 
• Giant cell myocarditis: sustained ventricular tachycardia in 
rapidly progressive heart failure, 
• Peripartum cardiomyopathy: heart failure developing in the 
last month of pregnancy or within 5 months following delivery. 
http://emedicine.medscape.com/article/156330-overview 
Diagnosis 
(Instrumental)  
https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
• Chest X-Ray: visualizing cardiac enlargement and pulmonary 
congestion.  
• Electrocardiography (ECG):  abnormal ST-T waves, conduction 
block, gradual increase in the width of the QRS complex, 
potentially fatal arrhythmias.  
• Echocardiography: transient wall thickening, reduced wall motion, 
reduced cardiac chamber size, pericardial effusion. 
• Cardiac Magnetic Resonance (CMR) and magnetic resonance 
imaging (MRI): visualization the regions of the heart affected by 
inflammation.  
• Cardiac catheterization including endomyocardial biopsy: to 
detect myocardial degeneration, myocyte necrosis, inflammatory 
infiltrates, and/or interstitial edema of the myocardium.   
Diagnosis 
(ECG)  
http://www.isarherzzentrum.de/en/myocarditis 
Ventricular tachycardia (rapid ventricular rhythm disorder) in 
myocarditis. 
Diagnosis 
(Echocardiography)  
http://www.isarherzzentrum.de/en/myocarditis 
Circulatory disorder (red) in an acute myocarditis. 
Diagnosis 
(Magnetic Resonance Imaging)  
http://www.isarherzzentrum.de/en/myocarditis 
Representation of edema in acute myocarditis (arrow indicators). 
A pericardial effusion, aka fluid around the heart (star). 
Diagnosis 
(Endomyocardial Biopsy)  
http://www.isarherzzentrum.de/en/myocarditis 
Hematoxylin and eosin staining of the biopsy sample reveals 
extensive myocyte necrosis, cellular inflammation and the 
formation of multinucleated giant cells (arrows). 
Diagnosis 
(Diagnostic Criteria for Acute Myocarditis in 
Endomyocardial Biopsy) 
https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
• Infiltration of many large or small mononuclear cells* 
(occasionally, a few polymorphonuclear leukocytes and 
multinucleated giant cells appear). 
• Rupture, fusion and disappearance of cardiomyocytes. 
• Interstitial edema (occasionally with fibril formation). 
 
*Cell infiltrates are often observed adjacent to cardiomyocytes. 
Diagnosis 
(Laboratory Studies)  
http://emedicine.medscape.com/article/156330-overview 
• Complete blood count (CBC): leukocytosis (may demonstrate 
eosinophilia), 
• Elevated erythrocyte sedimentation rate (and other acute 
phase reactants, such as C-reactive protein), 
• Rheumatologic screening : to rule out systemic inflammatory 
diseases, 
• Elevated cardiac enzymes: transient elevation of C-reactive 
protein (CRP), aspartate aminotransferase (AST), lactate 
dehydrogenase (LDH), the MB form creatine kinase (CK-MB), 
and cardiac troponin T in blood; troponin T is especially useful 
for immediate diagnosis, however, which type of it, T or I, is 
more useful for diagnosis has not been determined. 
• Serum viral antibody titers: for viral myocarditis. 
Diagnosis 
(Viral Infection) 
  
https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
• Viral infection is confirmed if the viral antibody titer is at least 
four times higher in an acute phase serum sample than in a 
sample obtained in remission phase collected at least two 
weeks apart.  
• However, only approximately 10% of patients with viral 
infection exhibit a positive antibody titer.  
• Polymerase chain reaction (PCR) is more useful for identifying 
the genomes of viruses causing myocarditis, but is not 
commonly performed. 
Diagnosis 
(Differential Diagnoses) 
  
http://emedicine.medscape.com/article/156330-differential 
• Alcoholic Cardiomyopathy 
• Cardiac Tamponade 
• Cardiogenic Shock 
• Chagas Disease (American Trypanosomiasis) 
• Cocaine-Related Cardiomyopathy 
• Coronary Artery Atherosclerosis 
• Dilated Cardiomyopathy 
• Hypertrophic Cardiomyopathy 
• Peripartum Cardiomyopathy 
• Restrictive Cardiomyopathy 
Treatment 
(Diet and Physical Activity) 
• Patients should consume a low-sodium diet similar to that for 
heart failure management.   
• Physical activity should be restricted to reduce the work of the 
heart during the acute phase of myocarditis, especially when 
there is fever, active systemic infection, or heart failure. 
• Terms of physical activity limitation: 
• 10 – 14 days – mild myocarditis (up to ECG normalization), 
•   4 – 6 weeks – moderate myocarditis (up to normalization of 
heart size), 
• individually – severe myocarditis (up to decreasing of HF 
severity and disappearance of rhythm disorders).  
http://emedicine.medscape.com/article/156330-treatment  https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
Treatment 
(Tasks) 
Myocarditis is  treated in three ways: (1) intervention to eliminate 
the cause, (2) intervention to improve hemodynamic compromise, 
and (3) intervention in cardiac dysfunction. 
https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
Treatment 
(Etiotropic) 
• Antibiotic therapy only after the confirmation of the etiological 
factor (diphtheria). 
• Antiviral drugs only for proven viral myocarditis (etiologic agent 
is known AND sensitive to antiviral drug), however, beneficial 
effects are seen only if therapy is started prior to inoculation or 
soon thereafter.  
• Nevertheless, antiviral therapy may be considered in acute, 
fulminant myocarditis, in institutional outbreaks and in 
laboratory-acquired cases. 
https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
Treatment 
(Intensive Immunosuppressive Therapy) 
• Intensive immunosuppressive therapy (e.g., corticosteroids, 
azathioprine, cyclosporine, muromonab-CD3/OKT3) has been 
shown to have some benefit only in small-scale clinical studies 
in the treatment of giant cell myocarditis and has not been 
validated in large clinical trials.  
• At this time, immunosuppressive therapy is not recommended 
for myocarditis until clear evidence is available from the results 
of multicenter trials. 
http://emedicine.medscape.com/article/156330-overview 
Treatment 
(Pathogenetic Pharmacotherapy) 
• Vasodilators (e.g., nitroglycerin, sodium nitroprusside), 
• Angiotensin-converting enzyme inhibitors (e.g., enalapril) 
• Diuretics (e.g., furosemide), 
• Anticoagulation may be advisable as a preventive measure, 
although no definitive evidence is available, 
• Antiarrhythmics can be used cautiously, although most 
antiarrhythmic drugs have negative inotropic effects that may 
aggravate heart failure; supraventricular arrhythmias should be 
converted electrically, 
• Inotropic drugs (e.g., dobutamine, milrinone) may be necessary 
for severe decompensation, although they are highly 
arrhythmogenic. 
http://emedicine.medscape.com/article/156330-overview 
Treatment 
(Supportive Care and Surgical Intervention) 
• Hemodynamic and cardiac monitoring, 
• Administration of supplemental oxygen, 
• Fluid management, 
• Temporary transvenous pacing for complete heart block, 
• Cardiac transplantation, 
• Extreme cases: ventricular assist device or percutaneous 
circulatory support; left ventricular assistive devices (LVADs) 
and extracorporeal membrane oxygenation. 
 
http://emedicine.medscape.com/article/156330-overview 
Consultations 
• Cardiothoracic surgery, 
• Infectious disease 
and/or rheumatology 
consultations. 
http://emedicine.medscape.com/article/156330-treatment 
Rheumatic heart disease. 
Prognosis  
• In the acute phase, myocarditis management of cardiac pump 
failure and potentially fatal arrhythmias is the main clinical 
challenge.  
• The prognosis of myocarditis varies depending on the 
pathogenesis and type of disease. 
• Patients who survive fulminant myocarditis have a good 
prognosis.  
• Predictors of death or need for heart transplantation include 
syncope, low ejection fraction, and left bundle-branch block, 
all indicators of advanced cardiomyopathy. 
https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-88-0008/_pdf 
Prophylaxis 
• Vaccination should reduce the incidence of myocarditis 
caused by measles, rubella, mumps, poliomyelitis, and 
influenza.  
• The development of vaccines for other cardiotropic viruses 
may prevent viral myocarditis in the future. 
http://emedicine.medscape.com/article/156330-treatment 
Abbreviations  
 ACE - angiotensin converting 
enzyme 
CMR - cardiac magnetic 
resonance 
ECG - electrocardiogram  
MRI - magnetic resonance 
imaging 
HIV - human immunodeficiency 
virus 
LVADs - left ventricular assistive 
devices   
  
Diagnostic and treatment guidelines 
Current state of knowledge on etiology, diagnosis, management, 
and therapy of myocarditis: a position statement of the 
European Society of Cardiology Working Group on Myocardial 
and Pericardial Diseases 
Guidelines for Diagnosis and Treatment of Myocarditis    
 2015 ESC Guidelines for the management of infective 
endocarditis 
2015 ESC Guidelines for the diagnosis and management of 
pericardial diseases 
Update on Myocarditis 
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http://library.med.utah.edu/WebPath/CVHTML/CV093.html 
A large, dilated left ventricle typical of a 
dilated, or congestive, cardiomyopathy.   
Definition  
Cardiomyopathies are defined by structural and functional 
abnormalities of the ventricular myocardium that are 
unexplained by flow-limiting coronary artery disease or abnormal 
loading conditions and historically have been subdivided into 
primary disease, in which the heart is the only involved organ, 
and secondary forms where the cardiomyopathy is a 
manifestation of a systemic disorder.   
http://eurheartj.oxfordjournals.org/content/early/2014/08/28/eurheartj.ehu284  
Epidemiology  
(Dilated Cardiomyopathy) 
 emedicine.medscape.com/article/2017823-overview#a3 heart.org/HEARTORG/Conditions/More/Cardiomyopathy/Dilated-Cardiomyopathy_UCM_444187_Article.jsp#.V34FCLiLQhc 
• The estimated prevalence of dilated cardiomyopathy (DCM) is 
1:2500. 
• The incidence of DCM discovered at autopsy is estimated to 
be 4.5 cases per 100,000 population per year, whereas the 
clinical incidence is 2.45 cases per 100,000 population per 
year. 
• DCM is the most common type, occurring mostly in adults 20 
to 60.  
• Men are more likely in men than in women. 
Epidemiology  
(Hypertrophic Cardiomyopathy) 
http://bestpractice.bmj.com/best-practice/monograph/409/basics/epidemiology.html 
• Hypertrophic cardiomyopathy (HCM) occurs with an incidence 
of 1 in 500 people in the general population and is the most 
common cause of sudden death in children and adults under 
35 years. 
• The mean age is 57 (16 to 87) years.  
• HCM is autosomal dominant with no known sex predilection. 
• Sudden death is most common in young patients, and death 
from heart failure or stroke occurs more frequently in middle 
age and beyond. 
• Apical HCM is seen much more commonly in Asian people.   
Epidemiology 
(Distribution of Myocardial Diseases According to the 
Manner of Death)   
http://www.revespcardiol.org/en/myocardial-disease-mortality-in-children/articulo/13086406/ 
Risk Factors and Etiology 
(Dilated Cardiomyopathy)   
• DCM can be familial, primary without family history, or secondary 
(associated with or caused by other conditions).  
• Familial DCM (at least 25% of cases of DCM), is usually autosomal 
dominant, with X-linked autosomal recessive and mitochondrial 
inheritance occurring less frequently. 
• Approximately 2 of 3 patients have no known family history 
(sporadic DCM) and about 15% of sporadic cases arise from chronic 
myocarditis, leading to scarring and heart failure.   
• Noninflammatory etiologies and associations include alcoholism, 
anthracycline drugs, ingestion of metals, autoimmune and systemic 
disorders, and mitochondrial disorders. 
• The distinction between the cause and risk factor(s) DCM is 
sometimes blurred. 
http://emedicine.medscape.com/article/2017823-overview#a2 
Risk Factors and Etiology 
(Hypertrophic Cardiomyopathy)   
• Abnormal calcium kinetics leads to the inappropriate myocardial 
hypertrophy and specific features of HCM, particularly in patients 
with diastolic functional abnormalities (abnormal myocardial 
calcium kinetics and abnormal calcium fluxes from an increase in 
the number of calcium channels result in an increase in intracellular 
calcium concentration, which may produce hypertrophy). 
• Genetic causes: familial HCM occurs as an autosomal dominant 
Mendelian-inherited disease in approximately 50% of cases (at least 
6 different genes on at least 4 chromosomes are associated with 
HCM, with more than 50 different mutations discovered thus far). 
Familial HCM. 
• Other possible causes: abnormal sympathetic stimulation; 
abnormally thickened intramural coronary arteries; subendocardial 
ischemia; cardiac structural abnormalities.   
http://emedicine.medscape.com/article/152913-overview 
Risk Factors and Etiology 
(Diverse Etiology of Hypertrophic Cardiomyopathy)   
  
http://eurheartj.oxfordjournals.org/content/early/2014/08/28/eurheartj.ehu284 
Mechanisms 
(Dilated Cardiomyopathy: Gross Findings)    
  
http://emedicine.medscape.com/article/2017823-overview#a9 
• Cardiomegaly is a requisite for the diagnosis of DCM (the mean 
heart weight is about 600 g). 
• Typically, 4-chamber dilatation that is greater in the ventricles 
than the atria is found.   
• LV wall thickness is often normal, in contrast to hypertensive 
cardiomyopathy with failure.  
• Mitral insufficiency may result from papillary muscle dysfunction 
secondary to LV and changes in LV wall shape, and tricuspid 
regurgitation results from annular dilatation. 
• Mural thrombi are common in patients who do not receive 
anticoagulation.  
• Mild diffuse or patchy endocardial fibrosis is frequent and is likely 
a result of cardiac dilatation. 
Mechanisms 
(Dilated Cardiomyopathy: Gross Findings)    
  
http://emedicine.medscape.com/article/2017823-overview#a9 
Gross heart specimen from a patient with DCM who died in end-
stage heart failure. Defibrillator leads are in the right heart. The 
ventricles are dilated more than the atria. 
Mechanisms 
(Dilated Cardiomyopathy: Microscopic Findings)    
  
http://emedicine.medscape.com/article/2017823-overview#a9 
• The histologic features of DCM are nonspecific; therefore, it is a 
microscopic diagnosis of exclusion.  
• In biopsies, the findings range from minimal variation in myocyte 
size to typical features of myofiber loss, interstitial fibrosis, and 
marked variation in myofiber size.  
• Transmural scars may also occur in dilated cardiomyopathy.  
• Quantitation of collagen has shown up to 4 times the normal 
collagen concentration, with a decrease in mature cross-linked 
collagen, correlating with an increase in neutrophil-type 
collagenase activity. 
• The volume density of myofibrils is reduced, and mitochondrial 
density is normal, but the mitochondria are more numerous and 
small.  
 
Mechanisms 
(Dilated Cardiomyopathy: Microscopic Findings)    
  
http://emedicine.medscape.com/article/2017823-overview#a9 
Heart section from a cardiac explant in a patient with end-stage 
DCM. There is focal interstitial fibrosis. The change is nonspecific 
and can be seen in heart failure from any cause. 
Mechanisms 
(Dilated Cardiomyopathy: Immunohistochemistry)    
  
http://emedicine.medscape.com/article/2017823-overview#a9 
• Immunolocalization of sarcomeric and cytoskeletal proteins have 
demonstrated abnormal distribution in explanted hearts from 
patients with DCM.  
• Tubulin and desmin are increased in amount and irregularly 
distributed. 
• Titin, a member of the sarcomeric skeleton family, is reduced, 
usually in areas where contractile material is lacking. 
• Connexin-43 is also decreased. 
• Increased myocyte cell death and apoptosis is found. 
• In cases of dystrophin-related dilated cardiomyopathy (up to 6% 
in males with dilated cardiomyopathy), immunohistochemical 
and molecular studies are essential to identify protein and gene 
defects. 
Mechanisms 
(Dilated Cardiomyopathy: Immunohistochemistry)    
  
http://emedicine.medscape.com/article/2017949-overview 
Arrhythmogenic right ventricular cardiomyopathy (ARVC).  
Mechanisms 
(Hypertrophic Cardiomyopathy: Gross Findings)  
http://pathologyoutlines.com/topic/hearthypertrophic.html 
• About 1/4 individuals with HCM demonstrate an obstruction to 
the outflow of blood from the LV during rest and in 70% of 
patients, obstruction can be provoked under certain conditions 
(dynamic outflow obstruction). 
• Myocardial hypertrophy and extracellular fibrosis predispose to 
increased LV stiffness which in concert with compromised cellular 
energetics and abnormal calcium handling lead to diastolic 
dysfunction manifested as dyspnea and exercise intolerance 
• The altered structure of the coronary vessels and increased 
diastolic pressure (reduced blood supply), with the hypertrophy 
and outflow tract obstruction (increased demand), may cause 
myocardial ischemia manifested as angina, and may trigger 
ventricular arrhythmias. 
Mechanisms 
(Hypertrophic Cardiomyopathy: Gross Findings) 
http://www.pathguy.com/sol/07811.jpg 
Mechanisms 
(Hypertrophic Cardiomyopathy: Microscopic Findings)  
http://pathologyoutlines.com/topic/hearthypertrophic.html 
• The earliest histological changes are myocyte disorganization / 
disarray which is widespread throughout the ventricles. 
• The interventricular septum demonstrates myocyte disarray, the 
hallmark of HCM. 
• The abnormal arrangement of large hypertrophied muscle 
bundles crossing each other. 
• The most sensitive and specific change is circular arrays of 
myocytes around central foci of connective tissue . 
• Cross sections of the sarcomere show a highly organized 
orthohexagonal array, with six thin actin filaments surrounding 
one thick myosin filament. 
•  The abnormal myosin interferes with the normal spatial 
arrangement of the myofibril.  
 
Mechanisms 
(Hypertrophic Cardiomyopathy: Microscopic Findings) 
http://www.wikidoc.org/index.php/File:3480.jpg 
Interstitial fibrosis with many fibroblastic cells. 
Mechanisms 
(Hypertrophic Cardiomyopathy: Pathophysiology)  
http:// http://emedicine.medscape.com/article/152913-overview#a3 
• The greatest factor in HCM is the dynamic pressure gradient across the 
LV outflow tract.   
• Three explanations for the systolic anterior motion of the mitral valve 
(MV) have been offered: (1) the MV is pulled against the septum by 
contraction of the papillary muscles, which occurs because of the 
valve's abnormal location and septal hypertrophy altering the 
orientation of the papillary muscles; (2) the MV is pushed against the 
septum because of its abnormal position in the outflow tract; (3) the 
MV is drawn toward the septum because of the lower pressure that 
occurs as blood is ejected at high velocity through a narrowed outflow 
tract (Venturi effect). 
• Most patients with HCM have abnormal diastolic function (whether or 
not a pressure gradient is present), which impairs ventricular filling and 
increases filling pressure, despite a normal or small ventricular cavity.   
Mechanisms 
(Hypertrophic Cardiomyopathy: Pathophysiology) 
http://thoracickey.com/hypertrophic-cardiomyopathy-2/ 
Dynamic changes in left ventricular outflow tract obstruction. Ao, 
ascending aorta; LA, left atrium; LV, left ventricle. 
Classification 
(International Classification of Diseases (ICD): 1) 
apps.who.int/classifications/icd10/browse/2016/en#/I46 
142 Cardiomyopathy 
I42.0 Dilated (congestive) 
cardiomyopathy  
I42.1 Obstructive hypertrophic 
cardiomyopathy (hypertrophic 
subaortic stenosis) 
I42.2 Other (nonobstructive) 
hypertrophic cardiomyopathy  
I42.3 Endomyocardial (eosinophilic) 
disease  
I42.4 Endocardial fibroelastosis 
(congenital cardiomyopathy) 
I42.5 Other restrictive 
cardiomyopathy  
I42.6 Alcoholic cardiomyopathy 
  
 I42.7 Cardiomyopathy due to drugs 
and other external agents  
I42.8 Other cardiomyopathies 
I42.9 Cardiomyopathy, unspecified  
I43* Cardiomyopathy in diseases 
classified elsewhere 
I43.0* Cardiomyopathy in infectious 
and parasitic diseases classified 
elsewhere 
I43.1*Cardiomyopathy in metabolic 
diseases  
I43.2*Cardiomyopathy in nutritional 
diseases  
I43.8*Cardiomyopathy in other 
diseases classified elsewhere  
Classification 
(Primary and Secondary) 
https://en.wikipedia.org/wiki/Cardiomyopathy 
• Primary/intrinsic cardiomyopathies 
• Genetic (HCM, arrhythmogenic right ventricular 
cardiomyopathy (ARVC), left ventricle (LV) non-compaction, 
Ion Channelopathies, DCM, restrictive cardiomyopathy (RCM) 
• Acquired (stress cardiomyopathy, myocarditis, ischemic 
cardiomyopathy) 
• Secondary/extrinsic cardiomyopathies: metabolic/storage 
(Fabry’s disease, hemochromatosis), endomyocardial 
(endomyocardial fibrosis, hypereosinophilic syndrome), 
endocrine (diabetes mellitus, hyperthyroidism, acromegaly), 
cardiofacial (noonan syndrome), neuromuscular (muscular 
dystrophy, Friedreich’s ataxia), other (obesity-associated 
cardiomyopathy). 
Classification 
(World Health Organization Classification) 
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/dilated-restrictive-cardiomyopathy/ 
Type   Features Causative Factors 
Dilated Dilated left or both 
ventricle(s), with impaired 
contraction 
Ischemic, idiopathic, familial-genetic, 
immune, alcoholic, toxic, valvular 
Hypertrophic Left or right ventricular 
hypertrophy, or both 
Familial, with autosomal dominant 
inheritance 
Restrictive Restrictive filling and reduced 
diastolic filling of one or both 
ventricles  
Idiopathic, amyloidosis, 
endomyocardial fibrosis 
Arrhythmogenic 
right ventricular 
cardiomyopathy 
Fibrofatty replacement of 
right ventricular myocardium, 
Uhl's anomaly (parchment 
heart) 
Unknown; familial, with incomplete 
penetrance; possible autosomal 
recessive inheritance; rare forms (eg, 
Naxos disease) 
Unclassified Not typical for previous four 
groups 
Fibroelastosis, noncompacted 
myocardium, systolic dysfunction with 
minimal dilation, mitochondrial disease 
 
 
Clinical Investigation  
(Signs and Symptoms) 
Dilated Cardiomyopathy 
• Some patients remain 
asymptomatic throughout 
life. 
• Some patients have severe 
symptoms of heart failure; 
arrhythmias; systemic 
embolism; angina, but only 
in the presence of ischemic 
heart disease.   
 
Hypertrophic Cardiomyopathy 
• Some patients remain 
asymptomatic throughout 
life. 
• Some patients have severe 
symptoms of heart failure, 
arrhythmias, systemic 
embolism. 
• Some patients die suddenly, 
often in the absence of 
previous symptoms. 
en.wikipedia.org/wiki/Dilated_cardiomyopathy#Signs_and_symptoms pathologyoutlines.com/topic/heartdilated.html pathologyoutlines.com/topic/hearthypertrophic.html 
Diagnosis 
(Dilated Cardiomyopathy) 
  
https://en.wikipedia.org/wiki/Dilated_cardiomyopathy#Signs_and_symptoms clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/cardiac-arrhythmias/ 
• DCM is characterized by enlargement of the heart with a 
decreased shortening fraction (usually less than 25%), sinus 
tachycardia or atrial fibrillation,  left bundle-branch 
block (LBBB).   
• Genetic testing can help understand the underlying cause of 
the DCM. 
• DCM is usually identified when limiting symptoms are severe, 
but arrhythmias or sudden death are uncommonly early 
manifestations. 
• In contrast to arrhythmogenic and hypertrophic 
cardiomyopathy, arrhythmias in DCM are typically prominent 
only after the onset of significant heart failure. 
• A family history of DCM is present in over 50% of patients. 
Diagnosis 
(Dilated Cardiomyopathy) 
  
https://en.wikipedia.org/wiki/Dilated_cardiomyopathy#Signs_and_symptoms clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/cardiac-arrhythmias/ 
• DCM is characterized by enlargement of the heart with a 
decreased shortening fraction (usually less than 25%), sinus 
tachycardia or atrial fibrillation,  left bundle-branch 
block (LBBB).   
• Genetic testing can help understand the underlying cause of 
the DCM. 
• DCM is usually identified when limiting symptoms are severe, 
but arrhythmias or sudden death are uncommonly early 
manifestations. 
• In contrast to arrhythmogenic and hypertrophic 
cardiomyopathy, arrhythmias in DCM are typically prominent 
only after the onset of significant heart failure. 
• A family history of DCM is present in over 50% of patients. 
Diagnosis 
(Dilated Cardiomyopathy with Mural Thrombus) 
  
https://i.ytimg.com/vi/FtcDPkKE6to/hqdefault.jpg 
Diagnosis 
(Dilated Cardiomyopathy following Trastuzumab 
Chemotherapy) 
http://medind.nic.in/ibi/t12/i1/ibit12i1p131.htm 
Diagnosis 
(Dilated Cardiomyopathy: The Veteran Athlete’s Heart) 
  
http://www.aspetar.com/journal/viewarticle.aspx?id=33#.V39bWLiLQhc 
Diagnosis 
(Dilated Cardiomyopathy: Chest Radiograph) 
  
http://emedicine.medscape.com/article/348284-overview 
Diagnosis 
(Hypertrophic Cardiomyopathy) 
  
http://emedicine.medscape.com/article/152913-overview#showall 
• No specific laboratory blood tests are required in the workup.  
• Genetic testing is not yet widely available. 
• Imaging modalities data: abnormal systolic anterior leaflet 
motion of the mitral valve, LV hypertrophy, left atrial 
enlargement, small ventricular chamber size, septal 
hypertrophy with septal-to-free wall ratio greater than 1.4:1, 
mitral valve prolapse and mitral regurgitation, decreased 
midaortic flow, partial systolic closure of the aortic valve in 
midsystole. 
• Electrocardiography (ECG): ST-T wave abnormalities and LVH, 
axis deviation, conduction abnormalities, sinus bradycardia with 
ectopic atrial rhythm, atrial enlargement, abnormal and 
prominent Q wave in the anterior precordial and lateral limb 
leads, atrial fibrillation,  etc. 
 
 
 
Diagnosis 
(Hypertrophic Cardiomyopathy) 
http://2.bp.blogspot.com/-FLBZEezZ9kg/VBSgVem1leI/AAAAAAAABx4/Ztwyi3saNtE/s1600/cardiaccompassmmodewithwithleftventricalcalc.jpeg 
Diagnosis 
(Hypertrophic Cardiomyopathy) 
http://www.med.umich.edu/lrc/coursepages/m1/anatomy2010/html/clinicalcases/cardiomegaly/cardiomegaly.html 
Diagnosis 
(Hypertrophic Cardiomyopathy: Midventricular 
Obstructive) 
http://journals.lww.com/jcardiovascularmedicine/Abstract/2015/11000/Clinical_characteristics_and_prognosis_of_60.4.aspx 
Abnormal ECG in a patient with hypertrophic cardiomyopathy. Note the T wave 
inversion and ST depression in the inferolateral leads (arrows) 
Diagnosis 
(Hypertrophic Cardiomyopathy in Athletes) 
  
http://emedicine.medscape.com/article/348284-overview 
Abnormal ECG in a patient with hypertrophic cardiomyopathy. Note the T wave 
inversion and ST depression in the inferolateral leads (arrows) 
Treatment 
(Dilated Cardiomyopathy) 
• Essentially the same as treatment of chronic heart failure (HF). 
• Drug therapy can slow down progression and in some cases 
even improve the heart condition and may include salt 
restriction, angiotensin converting enzyme (ACE) 
inhibitors, diuretics, anticoagulants. 
• Surgery: artificial pacemakers;  implantable cardioverter-
defibrillators;  ventricular remodeling, heart 
transplantation may be considered.  
 
https://en.wikipedia.org/wiki/Dilated_cardiomyopathy#Signs_and_symptoms 
Treatment 
(Hypertrophic Cardiomyopathy) 
• A significant number of patients do not have any symptoms and 
will have normal life expectancies, though they should be 
counseled to avoid particularly strenuous activities or 
competitive athletics.  
• In patients with resting or inducible outflow obstructions, 
situations that will cause dehydration or vasodilation should be 
avoided.   
• The primary goal of medications is to relieve symptoms, and  
first-line agents include beta blockers and calcium channel 
blockers (verapamil). 
• Surgery: septal myectomy, septal ablation, implantable 
pacemaker or defibrillator, cardiac transplantation. 
 
 
 
https://en.wikipedia.org/wiki/Hypertrophic_cardiomyopathy#Treatment 
Prognosis  
• DCM:  survival rate of less than 50% at 10 years; there is a 
negative association  survival with frequent ventricular 
tachyarrhythmias that require antiarrhythmic treatment or 
automated implantable cardioverter-defibrillator (AICD) 
placement. 
• HCM: annual mortality rates of up to 6% , important 
independent predictors of mortality are mutations in the b-
MHC, occurrence of atrial fibrillation, stroke, presence of 
basal outflow obstruction of at least 30 mm Hg and marked 
left ventricular wall thickness of more than 25 mm.  
http://emedicine.medscape.com/article/2017823-overview#a4 http://pathologyoutlines.com/topic/hearthypertrophic.html 
Prophylaxis 
• Cardiomyopathy may be due to an underlying diseases or 
conditions.  
• Treating that conditions early enough may help prevent 
cardiomyopathy complications.  
• Sudden cardiac arrest (SCA) may be prevented in patients at 
high risk if they are treated with an implantable cardioverter 
defibrillator. 
 
en.wikipedia.org/wiki/Supraventricular_tachycardia#Medications 
Abbreviations  
ACE – angiotensin converting enzyme  
Ao -ascending aorta 
ARVC - arrhythmogenic right ventricular cardiomyopathy  
DCM - dilated cardiomyopathy  
ECG – electrocardiography 
HCM - hypertrophic cardiomyopathy 
HF - chronic heart failure 
LA - left atrium 
LBBB - left bundle-branch block  
LV - left ventricle 
MV - mitral valve  
SCA - sudden cardiac arrest 
 
Diagnostic and treatment guidelines 
2014 ESC Guidelines on diagnosis and management of 
hypertrophic cardiomyopathy 
Hypertrophic Cardiomyopathy 
Dilated Cardiomyopathy  
